
ACTU Stock Forecast & Price Target
ACTU Analyst Ratings
Bulls say
Actuate Therapeutics Inc has demonstrated significant improvement in overall survival (mOS) and one-year survival rates in patients with first-line metastatic pancreatic adenocarcinoma (mPDAC) when treated with elraglusib in combination with GnP, as presented at the 2025 ASCO annual meeting. The recent strengthening of the company's balance sheet through a fundraising initiative provides management with the financial flexibility to explore various regulatory pathways and potentially expedite the clinical development process for elraglusib. Additionally, the company's Phase 2 study results indicate a promising efficacy profile for elraglusib, suggesting that with further validation in larger trials, it could lead to favorable regulatory outcomes.
Bears say
Actuate Therapeutics has reported significant financial challenges, including rising operational costs that outpace revenue growth, leading to ongoing net losses. Additionally, the clinical stage of its therapeutic candidate, elraglusib, presents inherent risks associated with drug development, which may contribute to investor uncertainty and volatility in stock performance. Furthermore, the company's cash reserves raise concerns about its ability to fund continued research and development initiatives without securing additional financing, which could dilute existing shareholder value.
This aggregate rating is based on analysts' research of Actuate Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ACTU Analyst Forecast & Price Prediction
Start investing in ACTU
Order type
Buy in
Order amount
Est. shares
0 shares